The global sinus therapeutic drugs market will reach US$ 4.29 Bn by 2030, growing at a steady CAGR during 2020-2030, according to a research conducted by ESOMAR-certified firm, Future Market Insights (FMI)
The development of biologics is amongst the most important factors catalysing the sinus therapeutic drugs market. Omalizumab is garnering interest of researchers and drug manufacturers alike. It has obtained the approval all across the Europe and the US to treat severe allergic asthma.
In adults, sinus infections could be attributed to sinus glands having structural deformities, nasal polyps, and history of infection to respiratory tract, weakened immunity.
In children, sinus-related infections could be caused due to a pacifier, getting unduly exposed to second-hand smoke, feeding at the time of laying down, and likewise. Moreover, fungal infections and pollutants drive sinusitis.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-12367
Key Takeaways
- Steroid nasal sprays held the largest market share in 2019 and the scenario is expected to continue in the upcoming period as well.
- North America accounted for more than 30% of market share in 2019
- Antibiotics remain a first line of defence, and this category is likely to grow at steady pace through 2030
- Covid-19 outbreak has diverted the research towards nasal drug delivery, which is likely to benefit even sinus therapeutic drugs market.
Key Participant Insights
The global market is set to witness a staggering growth in the forecast period. The market players are batting for organic as well as inorganic mode of expansion.
For instance –
- In Jul 2020, Tiziana announced submission of patent application for Foralumab’s nasal administration. Foralumab is a 100% human Anti-CD3 monoclonal antibody to treat Covid-19 patients.
- In Jun 2019, Sanofi and Regeneron Pharmaceuticals, Inc. announced approval of Dupixent (dupilumab) by the US FDA to be used with the other medicines for treating CRSwNP (chronic rhinosinusitis with nasal polyposis).
The key market players covered by FMI include Bausch Health, Nоvаrtіѕ АG, Ѕun Рhаrmасеutісаl Іnduѕtrіеѕ, Іnс., Rеddу’ѕ Lаbоrаtоrіеѕ, Іnс., Теа Рhаrmасеutісаl Іnduѕtrіеѕ Ltd., Frеѕеnіuѕ Каbі UЅА, Јоhnѕоn & Јоhnѕоn, Рfіzеr Іnс., Јаnѕѕеn Рhаrmасеutісаlѕ, Іnс., and GlaxoSmithKline plc.
“Upsurge in drug delivery systems for ascertaining increased consumption of sinus therapeutic drugs to propel the market” – says the FMI Analyst.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-12367
Want more insights?
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global sinus therapeutic drugs market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The study provides compelling insights on sinus therapeutic drugs market on the basis of drug class (Аntіhіѕtаmіnеѕ, Аnаlgеѕісѕ, Ѕulрhоnаmіdеѕ, Соrtісоѕtеrоіdѕ, Аntіbіоtісѕ, NSAID’s, and Оthеr Drug Сlаѕѕеѕ), type of disease (Acute Sinusitis, Sub-acute Sinusitis, Chronic Sinusitis), route of administration (Oral, Topical, Injectable), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies) across seven major regions
Key Segment
Route of Administration
- Oral
- Topical
- Injectable
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Disease Type
- Acute Sinusitis
- Sub-acute Sinusitis
- Chronic Sinusitis
For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-12367
Geography
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa